Psilocybin
James Gilligan is Leading the Next Wave of Psilocybin – Podcast Episode #35
Welcome to the fourth season of the Psychedelic Invest Podcast! It’s great to be back! On the season premiere episode, host Bruce Eckfeldt is joined…
Welcome to the fourth season of the Psychedelic Invest Podcast! It’s great to be back!
On the season premiere episode, host Bruce Eckfeldt is joined by James Gilligan, the CEO of Tryp Therapeutics.
Jim received his Ph.D. in Pharmacology and Toxicology from the University of Connecticut; he continued his post graduate education at the Roche Institute of Molecular Biology
Following his postdoc, Jim was a co-founder of Unigene Labs, which became experts in the development of peptide based therapeutics. During his tenure at Unigene he oversaw the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies.
Jim transitioned from R&D to business development (BD) and during this time obtained a Masters in International Business from Seton Hall University (South Orange, NJ). As VP for product and business development he established a biotech joint venture in China. He was responsible for executing numerous feasibility and licensing deals with the Pharma Industry. As part of his BD responsibilities he worked frequently with investment bankers, venture capitalists, and brokers.
Following his time at Unigene Jim was a co-founder and CSO of Tarsa Therapeutics.
Stay tuned for more great Psychedelic Invest Podcast episodes… happening weekly.
If you just found out about the podcast, we encourage you to check out the Psychedelic Invest Podcast page or subscribe to the show on your favorite audio platform to binge and catch up.
The Transcription is Coming Soon
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders
-
Psychedelics1 week ago
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
-
Law & Regulation1 week ago
Adastra reports record sales in 2023, but remains in the red
-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin7 days ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend